# Australian Government

Type: organization

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/australian-government
Canonical HTML page: https://getbiobrief.com/entity/australian-government

## Recent coverage (2 stories)

### Novartis, Roche Face 50% PBS Price Cut on MS Drugs as Briumvi Triggers Review
2026-07-15 21:43:22 · Sentiment: Negative · Impact: 7/10 · Sources: 11

A July 2026 Australian PBS review for Roche's Ocrevus and Novartis’s Kesimpta could reduce government reimbursement by up to 50%, triggered by reference pricing with new low-cost entrant Briumvi. Manufacturers risk margin erosion or market withdrawal.
Full story: https://getbiobrief.com/story/pbs-ms-review-pharma

### Netflix-Style Subscription Model Proposed to Combat Rising Superbug Threat
2026-02-19 11:55:06 · Sentiment: Neutral · Impact: 7/10 · Sources: 3

Experts are calling for a radical shift in antibiotic procurement, moving toward a subscription-based 'Netflix model' to incentivize the development of new drugs against resistant superbugs. This approach aims to decouple pharmaceutical revenue from sales volume, ensuring a steady supply of critical treatments as antimicrobial resistance escalates globally.
Full story: https://getbiobrief.com/story/netflix-style-antibiotic-subscription-model

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.